A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
Antiretroviral Combinations Continue to Transform the Treatment Landscape
NEW YORK, Oct. 13, 2014 /PRNewswire/ -- This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.
Key Findings
Human Immunodeficiency Virus (HIV) Antiretrovirals
The 2006 launch of Atripla, the first single-tablet regimen (STR) for the treatment of HIV infection, marked an important advancement in antiretroviral therapy (ART), significantly enhancing efficacy and reducing pill burden. Research has continued to build on this innovation, and patients now have at their disposal a number of STRs that are highly effective and have good tolerability. Researchers are seeking to develop novel antiretroviral combinations that have a high barrier to resistance and a low cross-resistance with existing drugs, and that are easy to administer (ideally once-daily dosing).
Given the advancements in treatment, viral breakthrough is not uncommon. Keys to maintaining viral suppression are patient adherence, strategically guided treatment choices, and novel drug development.
Promising candidates in late trials include Tobira Therapeutics' cenicriviroc with novel anti-inflammatory effects, and Gilead's tenofovir alafenamide (TAF), which could overcome the safety concerns associated with tenofovir.
Methodology and Scope
-This research service focuses on antiretroviral therapeutics for the treatment of infection by HIV/AIDS. It does not cover vaccines.
-A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
-The information contained in this research service was derived from published sources, including the following: disease organization Web sites; public health organization Web sites; company publications including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.
HIV Overview
Human immunodeficiency virus, a bloodborne infectious disease, remains a major global health and development threat. Incidence and prevalence remain highest in Sub-Saharan Africa, with the region accounting for about % of the estimated million people living with HIV globally.
HIV infection weakens the immune system by destroying CD4 cells, and can eventually lead to acquired immune deficiency syndrome (AIDS). This is the most advanced stage of HIV infection and can take up to years to develop. Although carriers of the virus may not exhibit any symptoms, they can still transmit it.
HIV is transmitted by direct exposure to contaminated blood and other bodily fluids. Potential exposure routes include needle-stick injuries, needle sharing, blood transfusions, dialysis, tattoos and piercings, mother-to-fetus transmission, and sexual contact. High-risk populations include those with potential occupational exposure, including healthcare workers, dentists, and first responders; those practicing risky behaviors (e.g., intravenous drug users); and recipients of invasive therapeutic procedures such as blood transfusions and organ transplants (before 1985 in the United States).
ART is highly effective at suppressing the virus and boosting infected individuals' immune systems, and at reducing the likelihood of transmission. Some million infected people are on ART; the global target is million by 2015. ART has recently been shown to be safe and effective for pre-exposure prophylaxis (PrEP) for HIV-negative people. It is not a cure, however, and must be taken for life due to the latent virus in reservoirs inaccessible to antiretrovirals.
Read the full report: http://www.reportlinker.com/p02231910-summary/view-report.html
About Reportlinker ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article